Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18539370 | 1.00 | BCDIN3D (0.47) | BCDIN3DKDM4EGBA1SOS1OPRL1 | |
| SCHEMBL3757143 | 1.00 | BCDIN3D (0.47) | BCDIN3DKDM4EGBA1SOS1OPRL1 | |
| SCHEMBL5575374 | 0.83 | KDM4E (0.59) | KDM4ESOS1 | |
| SCHEMBL9350980 | 0.83 | KDM4E (0.59) | KDM4ESOS1 | |
| SCHEMBL18539369 | 0.81 | KDM4E (0.43) | BCDIN3DKDM4ESOS1OPRL1GRIN2B | |
| SCHEMBL13946612 | 0.78 | KCNH3 (0.42) | BCDIN3DGBA1CSF1R | |
| SCHEMBL3753180 | 0.78 | KCNH3 (0.42) | BCDIN3DGBA1CSF1R | |
| SCHEMBL18539306 | 0.78 | ADRB2 (0.46) | BCDIN3DKDM4E | |
| SCHEMBL3639265 | 0.75 | SOS1 (0.67) | KDM4ESOS1OPRL1 | |
| SCHEMBL4689291 | 0.74 | GRIN2B (0.43) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | BCDIN3D 1624/4885KDM4E 3689/4885GBA1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.